GPR65 has also been linked to intratumoral exhausted CD8+ T cells, which suggests that developing GPR65 inhibitors or negative allosteric modulators may be clinically relevant in cancer immunotherapy (45, 46). This evidence concerns the gene CD8A and cancer.